Literature DB >> 22728050

Ascorbic acid: chemistry, biology and the treatment of cancer.

Juan Du1, Joseph J Cullen, Garry R Buettner.   

Abstract

Since the discovery of vitamin C, the number of its known biological functions is continually expanding. Both the names ascorbic acid and vitamin C reflect its antiscorbutic properties due to its role in the synthesis of collagen in connective tissues. Ascorbate acts as an electron-donor keeping iron in the ferrous state thereby maintaining the full activity of collagen hydroxylases; parallel reactions with a variety of dioxygenases affect the expression of a wide array of genes, for example via the HIF system, as well as via the epigenetic landscape of cells and tissues. In fact, all known physiological and biochemical functions of ascorbate are due to its action as an electron donor. The ability to donate one or two electrons makes AscH(-) an excellent reducing agent and antioxidant. Ascorbate readily undergoes pH-dependent autoxidation producing hydrogen peroxide (H(2)O(2)). In the presence of catalytic metals this oxidation is accelerated. In this review, we show that the chemical and biochemical nature of ascorbate contribute to its antioxidant as well as its prooxidant properties. Recent pharmacokinetic data indicate that intravenous (i.v.) administration of ascorbate bypasses the tight control of the gut producing highly elevated plasma levels; ascorbate at very high levels can act as prodrug to deliver a significant flux of H(2)O(2) to tumors. This new knowledge has rekindled interest and spurred new research into the clinical potential of pharmacological ascorbate. Knowledge and understanding of the mechanisms of action of pharmacological ascorbate bring a rationale to its use to treat disease especially the use of i.v. delivery of pharmacological ascorbate as an adjuvant in the treatment of cancer. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728050      PMCID: PMC3608474          DOI: 10.1016/j.bbcan.2012.06.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  254 in total

Review 1.  The antioxidant properties of serum albumin.

Authors:  Marjolaine Roche; Philippe Rondeau; Nihar Ranjan Singh; Evelyne Tarnus; Emmanuel Bourdon
Journal:  FEBS Lett       Date:  2008-05-12       Impact factor: 4.124

2.  Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells.

Authors:  Satya S Pathi; Ping Lei; Sandeep Sreevalsan; Gayathri Chadalapaka; Indira Jutooru; Stephen Safe
Journal:  Nutr Cancer       Date:  2011-09-15       Impact factor: 2.900

3.  The reaction of superoxide, formate radical, and hydrated electron with transferrin and its model compound, Fe(III)-ethylenediamine-N,N'-bis[2-(2-hydroxyphenyl)acetic acid] as studied by pulse radiolysis.

Authors:  G R Buettner
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

Review 4.  Cancer control and prevention by nutrition and epigenetic approaches.

Authors:  Mukesh Verma
Journal:  Antioxid Redox Signal       Date:  2012-01-30       Impact factor: 8.401

5.  Recycling of the ascorbate free radical by human erythrocyte membranes.

Authors:  J M May; Z Qu; C E Cobb
Journal:  Free Radic Biol Med       Date:  2001-07-01       Impact factor: 7.376

6.  Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Authors:  Carlos A Gonzalez; Elio Riboli
Journal:  Eur J Cancer       Date:  2010-09       Impact factor: 9.162

Review 7.  Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage.

Authors:  Bruce N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

8.  Vitamin B12b increases the cytotoxicity of short-time exposure to ascorbic acid, inducing oxidative burst and iron-dependent DNA damage.

Authors:  Marina E Solovieva; Valery V Soloviev; Vladimir S Akatov
Journal:  Eur J Pharmacol       Date:  2007-03-30       Impact factor: 4.432

Review 9.  Ascorbate and plasma membrane electron transport--enzymes vs efflux.

Authors:  Darius J R Lane; Alfons Lawen
Journal:  Free Radic Biol Med       Date:  2009-06-06       Impact factor: 7.376

10.  High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis.

Authors:  Chang-Hwan Yeom; Gunsup Lee; Jin-Hee Park; Jaelim Yu; Seyeon Park; Sang-Yeop Yi; Hye Ree Lee; Young Seon Hong; Joosung Yang; Sukchan Lee
Journal:  J Transl Med       Date:  2009-08-11       Impact factor: 5.531

View more
  247 in total

1.  Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.

Authors:  John A Cieslak; Zita A Sibenaller; Susan A Walsh; Laura L Boles Ponto; Juan Du; John J Sunderland; Joseph J Cullen
Journal:  Radiat Res       Date:  2015-12-31       Impact factor: 2.841

Review 2.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

3.  The latency of peroxisomal catalase in terms of effectiveness factor for pancreatic and glioblastoma cancer cell lines in the presence of high concentrations of H2O2: Implications for the use of pharmacological ascorbate in cancer therapy.

Authors:  Dieanira T Erudaitius; Garry R Buettner; Victor G J Rodgers
Journal:  Free Radic Biol Med       Date:  2020-06-06       Impact factor: 7.376

4.  Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.

Authors:  John A Cieslak; Robert K Strother; Malvika Rawal; Juan Du; Claire M Doskey; Samuel R Schroeder; Anna Button; Brett A Wagner; Garry R Buettner; Joseph J Cullen
Journal:  Free Radic Biol Med       Date:  2015-02-26       Impact factor: 7.376

Review 5.  Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue.

Authors:  Joshua D Schoenfeld; Matthew S Alexander; Timothy J Waldron; Zita A Sibenaller; Douglas R Spitz; Garry R Buettner; Bryan G Allen; Joseph J Cullen
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

6.  First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.

Authors:  Bryan G Allen; Kellie L Bodeker; Mark C Smith; Varun Monga; Sonia Sandhu; Raymond Hohl; Thomas Carlisle; Heather Brown; Nancy Hollenbeck; Sandy Vollstedt; Jeremy D Greenlee; Matthew A Howard; Kranti A Mapuskar; Steven N Seyedin; Joseph M Caster; Karra A Jones; Joseph J Cullen; Daniel Berg; Brett A Wagner; Garry R Buettner; Mindi J TenNapel; Brian J Smith; Douglas R Spitz; John M Buatti
Journal:  Clin Cancer Res       Date:  2019-08-19       Impact factor: 12.531

7.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

8.  Ascorbic acid modulation of iron homeostasis and lysosomal function in trabecular meshwork cells.

Authors:  Ping Xu; Yizhi Lin; Kristine Porter; Paloma B Liton
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-19       Impact factor: 2.671

Review 9.  Breathing-in epigenetic change with vitamin C.

Authors:  Asun Monfort; Anton Wutz
Journal:  EMBO Rep       Date:  2013-03-15       Impact factor: 8.807

10.  Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.

Authors:  Niraj Shenoy; Tushar D Bhagat; John Cheville; Christine Lohse; Sanchari Bhattacharyya; Alexander Tischer; Venkata Machha; Shanisha Gordon-Mitchell; Gaurav Choudhary; Li-Fan Wong; LouAnn Gross; Emily Ressigue; Bradley Leibovich; Stephen A Boorjian; Ulrich Steidl; Xiaosheng Wu; Kith Pradhan; Benjamin Gartrell; Beamon Agarwal; Lance Pagliaro; Masako Suzuki; John M Greally; Dinesh Rakheja; R Houston Thompson; Katalin Susztak; Thomas Witzig; Yiyu Zou; Amit Verma
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.